Developer docs
API playgroundTry for free, no card

Search company profiles

Pharmidex

Full company profile

uuid000pzcq

Namestring
Pharmidex
Legal namestring
Pharmidex
Websiteurl
pharmidex.com
Company typeenum
Private
Founded yearint
2002
Descriptiontext

Pharmidex is a UK-based preclinical Contract Research Organisation (CRO) providing integrated drug discovery and development services to pharmaceutical and biotechnology companies. The company operates from a London headquarters for business development and corporate functions, with state-of-the-art preclinical facilities in Hertfordshire comprising an 800m²+ licensed in vivo vivarium and 300m²+ laboratory space. The firm holds a comprehensive regulatory stack — MHRA, AAALAC, GLP and GCP accreditations — that allows it to generate submission-grade preclinical and clinical data.

The core offering is organized around three integrated service pillars: Bioanalysis (biomarker analysis, discovery and regulatory bioanalysis, drug metabolism, flow cytometry on an Attune NxT acoustic cytometer, haematology on a Siemens ADVIA 2120, and physicochemical assessment using UHPLC-HRMS and LC-MS/MS); Preclinical Services (histology, inflammation models, in silico drug discovery, medical device testing, medicinal chemistry, pharmacokinetics, toxicology, and the vivarium facility itself); and Clinical Services (clinical chemistry on a Thermo Scientific Indiko Plus, haematology and regulatory bioanalysis). Therapeutic-area expertise spans CNS, oncology, stroke, respiratory, metabolic disorders (obesity, diabetes, NASH, ADPKD) and autoimmune disease. Recent commercial additions include Tailored Genetically Altered Breeding Solutions launched in May 2026.

Pharmidex operates a fee-for-service professional services model, billing clients per project or study under quote-based contracts negotiated through direct enterprise sales and senior-scientist-led business development. The customer base spans 400+ global clients across 24 countries, including Top 25 Pharma companies and multi-programme biotechnology firms requiring IND-enabling pharmacology, bioanalysis and safety support. The company markets via its website, conference participation (e.g., ATS 2026), email newsletter and LinkedIn. The firm is privately held with no disclosed external investors or ownership changes in the input data.

Short descriptiontext

Pharmidex is a UK-based preclinical Contract Research Organisation providing GLP, AAALAC and MHRA-accredited bioanalysis, preclinical and clinical services — including toxicology, pharmacokinetics, histology and biomarker analysis — to pharmaceutical, biotechnology and academic clients globally.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersLondon, United Kingdom
HQ citystring
London
HQ countrystring
United Kingdom
HQ regionstring
Europe
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
preclinical CRO services, drug discovery research, bioanalytical services, pharmacokinetics testing, toxicology studies
Industry5 codes
PRIMARYHLAGAAAB
Preclinical CROs (Discovery/Pharmacology/DMPK)
SECONDARYHLAGAFAC
DMPK / ADME & Bioanalysis
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Preclinical Services (Toxicology/Pharmacology/DMPK)
SECONDARYHLAGAAAC
Toxicology & Safety Assessment CROs (GLP)
SECONDARYHLAGAAAE
Central Laboratory & Clinical Trial Testing CROs
SECONDARYHLAGAAAL
Specialty Therapeutic-Area CROs (e.g., oncology/rare disease)
NAICS code1 code
  • Scientific Research and Development Services5417
SIC code1 code
  • Services-Commercial Physical & Biological Research8731
Product category
Preclinical Contract Research Services
Social media profiles2 records
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Preclinical Contract Research Services
TypeProfessional Services
Description

Fee-for-service preclinical CRO services including bioanalysis, preclinical studies, and clinical sample analysis billed per project or study contract

pharmidex.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Infrastructure, Technology or R&D, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Pharmidex is a UK-based preclinical Contract Research Organisation (CRO) that delivers fee-for-service drug discovery and development support across three integrated pillars: Bioanalysis (biomarker analysis, discovery and regulatory bioanalysis, drug metabolism, physicochemical assessment, flow cytometry, haematology), Preclinical Services (histology, inflammation, in silico drug discovery, medicinal chemistry, medical device testing, pharmacokinetics, toxicology, vivarium), and Clinical Services (clinical chemistry, haematology, regulatory bioanalysis). The company serves pharma, biotech, and academic clients with GLP-, GCP-, MHRA-, and AAALAC-accredited workflows across therapeutic areas including CNS, oncology, stroke, respiratory, metabolic, and autoimmune diseases.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • 17,000+ studies completed
+3 more records
Product overview1 text field

Pharmidex is a UK-based preclinical Contract Research Organisation (CRO) providing integrated drug discovery and development services. The company operates as a single-site, scientifically rigorous CRO focused on complex preclinical decision-making. The core offering consists of three integrated service pillars: Bioanalysis (including biomarker analysis, discovery bioanalysis, drug metabolism, flow cytometry, haematology, and regulatory bioanalysis), Preclinical Services (covering histology, inflammation, in silico drug discovery, medical device testing, medicinal chemistry, pharmacokinetics, toxicology, and vivarium facilities), and Clinical Services (including clinical chemistry, haematology, and regulatory bioanalysis). The company also provides specialised therapeutic area expertise in CNS, oncology, stroke, respiratory, metabolic disorders, and autoimmune diseases. Services are delivered under GLP and GCP compliance with MHRA and AAALAC accreditation.

Product and service1 record
1Bioanalysis
Scale indicator12 records

Each record includes

Type, Value, Description, Source

Partnership2 partners
1Multi-programme Biotech Partner
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Integrated pharmacology, bioanalysis, and safety support through IND-enabling programmes. Represents collaborative drug development partnerships with biotech companies.

pharmidex.com
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Standardised in vivo execution and centralised bioanalysis across academic institutions for translational research collaborations.

Recent move4 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Peers8 records
TypeBroad incumbent
Description

Global CRO/CDMO providing preclinical toxicology, bioanalysis, DMPK and integrated drug discovery. Broad incumbent competing with Pharmidex across virtually all service lines from larger, integrated platform.

TypeDirect peer
Description

UK-based preclinical CRO providing general toxicology, safety pharmacology and DMPK. Directly comparable UK competitor with overlapping GLP in vivo services and similar customer base.

TypeBroad incumbent
Description

Global preclinical and discovery CRO offering in vivo pharmacology, safety assessment, bioanalysis and DMPK across modalities. Most directly comparable incumbent in Pharmidex’s core preclinical CRO market, though vastly larger and broader in scope.

TypeDirect peer
Description

Preclinical CRO specialising in oncology and metabolic disease models, translational research and bioanalysis. Direct peer to Pharmidex’s oncology and metabolic therapeutic area services.

TypeDirect peer
Description

US-based preclinical CRO and research models provider offering toxicology, DMPK, bioanalysis and vivarium services. Highly comparable to Pharmidex on AAALAC-accredited in vivo toxicology and bioanalysis, primarily serving small-to-mid biopharma.

TypeBroad incumbent
Description

Global CRO providing integrated drug discovery, preclinical and bioanalytical services with strong UK presence. Closest large-scale peer to Pharmidex’s integrated preclinical + bioanalysis offering, competing on similar capabilities with broader geographic footprint.

TypeDirect peer
Description

UK-based CRO offering drug discovery, medicinal chemistry, DMPK and bioanalytical services. Comparable peer for Pharmidex’s preclinical and in silico discovery offerings, with overlapping customer segments in small-mid biopharma.

TypeBroad incumbent
Description

Global bioanalytical and laboratory testing services provider with significant preclinical and pharmacology operations. Broad incumbent competing with Pharmidex on bioanalysis, DMPK and central laboratory services.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers2 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles3 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance4 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Pharmidex

Preclinical Contract Research Servicespharmidex.com

Pharmidex is a UK-based preclinical Contract Research Organisation providing GLP, AAALAC and MHRA-accredited bioanalysis, preclinical and clinical services — including toxicology, pharmacokinetics, histology and biomarker analysis — to pharmaceutical, biotechnology and academic clients globally.

What Pharmidex does

Pharmidex is a UK-based preclinical Contract Research Organisation (CRO) providing integrated drug discovery and development services to pharmaceutical and biotechnology companies. The company operates from a London headquarters for business development and corporate functions, with state-of-the-art preclinical facilities in Hertfordshire comprising an 800m²+ licensed in vivo vivarium and 300m²+ laboratory space. The firm holds a comprehensive regulatory stack — MHRA, AAALAC, GLP and GCP accreditations — that allows it to generate submission-grade preclinical and clinical data.

The core offering is organized around three integrated service pillars: Bioanalysis (biomarker analysis, discovery and regulatory bioanalysis, drug metabolism, flow cytometry on an Attune NxT acoustic cytometer, haematology on a Siemens ADVIA 2120, and physicochemical assessment using UHPLC-HRMS and LC-MS/MS); Preclinical Services (histology, inflammation models, in silico drug discovery, medical device testing, medicinal chemistry, pharmacokinetics, toxicology, and the vivarium facility itself); and Clinical Services (clinical chemistry on a Thermo Scientific Indiko Plus, haematology and regulatory bioanalysis). Therapeutic-area expertise spans CNS, oncology, stroke, respiratory, metabolic disorders (obesity, diabetes, NASH, ADPKD) and autoimmune disease. Recent commercial additions include Tailored Genetically Altered Breeding Solutions launched in May 2026.

Pharmidex operates a fee-for-service professional services model, billing clients per project or study under quote-based contracts negotiated through direct enterprise sales and senior-scientist-led business development. The customer base spans 400+ global clients across 24 countries, including Top 25 Pharma companies and multi-programme biotechnology firms requiring IND-enabling pharmacology, bioanalysis and safety support. The company markets via its website, conference participation (e.g., ATS 2026), email newsletter and LinkedIn. The firm is privately held with no disclosed external investors or ownership changes in the input data.

Pharmidex firmographics

Firmographics
Name
Pharmidex
Legal name
Pharmidex
Website
https://pharmidex.com
Company type
Private
Founded year
2002
Operating status
Operating
Headcount range
11–50 employees
Short description
Pharmidex is a UK-based preclinical Contract Research Organisation providing GLP, AAALAC and MHRA-accredited bioanalysis, preclinical and clinical services — including toxicology, pharmacokinetics, histology and biomarker analysis — to pharmaceutical, biotechnology and academic clients globally.
Ownership category
akta.pro rank

Pharmidex industry classification

Industry
Product category
Preclinical Contract Research Services
NAICS
Scientific Research and Development Services (5417)
SIC
Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAGAAAB
Preclinical CROs (Discovery/Pharmacology/DMPK)
SECONDARYHLAGAFAC
DMPK / ADME & Bioanalysis
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Preclinical Services (Toxicology/Pharmacology/DMPK)
SECONDARYHLAGAAAC
Toxicology & Safety Assessment CROs (GLP)
SECONDARYHLAGAAAE
Central Laboratory & Clinical Trial Testing CROs
SECONDARYHLAGAAAL
Specialty Therapeutic-Area CROs (e.g., oncology/rare disease)

Keywords

  • Preclinical CRO services
  • Drug discovery research
  • Bioanalytical services
  • Pharmacokinetics testing
  • Toxicology studies

Where Pharmidex is headquartered

Location

Headquarters

HQ city
London
HQ country
United Kingdom
HQ region
Europe

Offices2 records

Markets served

Pharmidex business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Infrastructure, Technology or R&D, Operations, Marketing or Sales

Revenue model

  1. Preclinical Contract Research Services: Fee-for-service preclinical CRO services including bioanalysis, preclinical studies, and clinical sample analysis billed per project or study contract

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Pharmidex product offering

Product offering

Core offering

Pharmidex is a UK-based preclinical Contract Research Organisation (CRO) that delivers fee-for-service drug discovery and development support across three integrated pillars: Bioanalysis (biomarker analysis, discovery and regulatory bioanalysis, drug metabolism, physicochemical assessment, flow cytometry, haematology), Preclinical Services (histology, inflammation, in silico drug discovery, medicinal chemistry, medical device testing, pharmacokinetics, toxicology, vivarium), and Clinical Services (clinical chemistry, haematology, regulatory bioanalysis). The company serves pharma, biotech, and academic clients with GLP-, GCP-, MHRA-, and AAALAC-accredited workflows across therapeutic areas including CNS, oncology, stroke, respiratory, metabolic, and autoimmune diseases.

Product overview

Pharmidex is a UK-based preclinical Contract Research Organisation (CRO) providing integrated drug discovery and development services. The company operates as a single-site, scientifically rigorous CRO focused on complex preclinical decision-making. The core offering consists of three integrated service pillars: Bioanalysis (including biomarker analysis, discovery bioanalysis, drug metabolism, flow cytometry, haematology, and regulatory bioanalysis), Preclinical Services (covering histology, inflammation, in silico drug discovery, medical device testing, medicinal chemistry, pharmacokinetics, toxicology, and vivarium facilities), and Clinical Services (including clinical chemistry, haematology, and regulatory bioanalysis). The company also provides specialised therapeutic area expertise in CNS, oncology, stroke, respiratory, metabolic disorders, and autoimmune diseases. Services are delivered under GLP and GCP compliance with MHRA and AAALAC accreditation.

Differentiator

Problem solved

Functional benefit

Products and services

  • Bioanalysis

Quantifiable outcome

  • 17,000+ studies completed
  • +3 more outcomes

Companies that use Pharmidex

Customer profile

Named customers2 records

Segments3 records

Ideal customer profiles3 records

Pharmidex technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature5 records

Pharmidex partnerships and signals

Strategic signal

Partnerships

Two partnerships are on record, tiered core.

  • Multi-programme Biotech PartnercoreStrategic or Co-development PartnerIntegrated pharmacology, bioanalysis, and safety support through IND-enabling programmes. Represents collaborative drug development partnerships with biotech companies.
  • Academic ConsortiumcoreStrategic or Co-development PartnerStandardised in vivo execution and centralised bioanalysis across academic institutions for translational research collaborations.

Scale indicators12 records

Recent moves4 records

Expansion highlights4 records

Pharmidex competitors and assessment

Company assessment

Broad incumbents

  • WuXi AppTec: Global CRO/CDMO providing preclinical toxicology, bioanalysis, DMPK and integrated drug discovery. Broad incumbent competing with Pharmidex across virtually all service lines from larger, integrated platform.
  • Charles River Laboratories: Global preclinical and discovery CRO offering in vivo pharmacology, safety assessment, bioanalysis and DMPK across modalities. Most directly comparable incumbent in Pharmidex’s core preclinical CRO market, though vastly larger and broader in scope.
  • Pharmaron: Global CRO providing integrated drug discovery, preclinical and bioanalytical services with strong UK presence. Closest large-scale peer to Pharmidex’s integrated preclinical + bioanalysis offering, competing on similar capabilities with broader geographic footprint.
  • Eurofins Scientific: Global bioanalytical and laboratory testing services provider with significant preclinical and pharmacology operations. Broad incumbent competing with Pharmidex on bioanalysis, DMPK and central laboratory services.

Direct peers

  • Sequani: UK-based preclinical CRO providing general toxicology, safety pharmacology and DMPK. Directly comparable UK competitor with overlapping GLP in vivo services and similar customer base.
  • Crown Bioscience: Preclinical CRO specialising in oncology and metabolic disease models, translational research and bioanalysis. Direct peer to Pharmidex’s oncology and metabolic therapeutic area services.
  • Inotiv: US-based preclinical CRO and research models provider offering toxicology, DMPK, bioanalysis and vivarium services. Highly comparable to Pharmidex on AAALAC-accredited in vivo toxicology and bioanalysis, primarily serving small-to-mid biopharma.
  • Concept Life Sciences: UK-based CRO offering drug discovery, medicinal chemistry, DMPK and bioanalytical services. Comparable peer for Pharmidex’s preclinical and in silico discovery offerings, with overlapping customer segments in small-mid biopharma.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights7 records

Customer concentration

Pharmidex social profiles

Digital presence

Pharmidex compliance and trust

Trust signal

Compliance4 records

Pharmidex financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Pharmidex leadership team

Management profile

Number of profiles

Profiles3 records

Pharmidex funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Pharmidex M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Pharmidex

What does Pharmidex do?

Pharmidex is a UK-based preclinical Contract Research Organisation (CRO) that delivers fee-for-service drug discovery and development support across three integrated pillars: Bioanalysis (biomarker analysis, discovery and regulatory bioanalysis, drug metabolism, physicochemical assessment, flow cytometry, haematology), Preclinical Services (histology, inflammation, in silico drug discovery, medicinal chemistry, medical device testing, pharmacokinetics, toxicology, vivarium), and Clinical Services (clinical chemistry, haematology, regulatory bioanalysis). The company serves pharma, biotech, and academic clients with GLP-, GCP-, MHRA-, and AAALAC-accredited workflows across therapeutic areas including CNS, oncology, stroke, respiratory, metabolic, and autoimmune diseases.

Is Pharmidex a public or private company?

Pharmidex is a private company. It is classified as unknown and is currently operating.

When was Pharmidex founded?

Pharmidex was founded in 2002. It employs 11 to 50 people.

Where is Pharmidex based?

Pharmidex is headquartered in London, United Kingdom, in the Europe region.

How does Pharmidex make money?

One revenue line is on record: preclinical Contract Research Services.

Who are Pharmidex's main competitors?

Broad incumbents on record are WuXi AppTec, Charles River Laboratories, Pharmaron and Eurofins Scientific. Direct peers are Sequani, Crown Bioscience, Inotiv and Concept Life Sciences.

Does Pharmidex have an API?

No public API is recorded for Pharmidex.

What industry is Pharmidex in?

Pharmidex's product category is Preclinical Contract Research Services. Its primary akta.pro industry code is HLAGAAAB, Preclinical CROs (Discovery/Pharmacology/DMPK), with a secondary code of HLAGAFAC, DMPK / ADME & Bioanalysis. Its NAICS code is 5417 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals